Johnson & Johnson Surgical Vision
Johnson & Johnson Surgical Vision is the ophthalmic-surgery business associated with Johnson & Johnson, supplying products for cataract, refractive, and other eye procedures.
Last updated October 7, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Johnson & Johnson Surgical Vision is the surgical-ophthalmology business operated within Johnson & Johnson MedTech. Its activities trace substantially to Abbott Medical Optics, which Johnson & Johnson agreed to acquire in 2016 and completed acquiring in 2017. The transaction brought into Johnson & Johnson a portfolio covering cataract surgery, refractive surgery, laser vision correction, and related ophthalmic technologies. The acquired business was subsequently integrated into Johnson & Johnson's Vision organization and has commonly been described in corporate and market materials as Johnson & Johnson Vision Surgical or Johnson & Johnson Surgical Vision. The business is distinct from Johnson & Johnson Vision Care, whose principal focus is contact lenses. Surgical Vision instead serves ophthalmic surgeons, hospitals, ambulatory surgery centers, and eye-care professionals. Its product categories have included intraocular lenses used in cataract procedures, phacoemulsification and other cataract-surgery equipment, ophthalmic viscosurgical devices, excimer-laser systems and associated consumables for corneal refractive procedures, and diagnostic or surgical-support technologies. Product families associated with the business include TECNIS intraocular lenses, VERITAS vision systems, and the ELITA femtosecond laser platform, although product availability and organizational ownership can vary by market and over time. A major strategic rationale for the Abbott Medical Optics acquisition was to combine Johnson & Johnson's existing position in contact lenses with a broader ophthalmology platform. Johnson & Johnson described the transaction as expanding its vision-care presence and adding complementary surgical technologies. The surgical portfolio also gave the company exposure to procedure-based markets whose demand is influenced by cataract prevalence, aging populations, refractive-surgery adoption, ophthalmologist preferences, reimbursement, regulatory approvals, and hospital capital spending. The organization operates as part of a much larger corporate structure rather than as an independently listed company. Johnson & Johnson is a publicly traded United States healthcare company, while Surgical Vision is a business or brand within its MedTech operations. Public materials may use several related names, including Johnson & Johnson Vision, Johnson & Johnson Vision Surgical, and Johnson & Johnson Surgical Vision. Because the supplied subject has no single authoritative standalone Wikipedia article or independently reported corporate profile, this dossier treats it as the surgical-ophthalmology business associated with Johnson & Johnson Vision and the former Abbott Medical Optics platform, rather than as a separate public company.
History
Johnson & Johnson Surgical Vision developed from Johnson & Johnson's expansion into surgical ophthalmology through the acquisition of Abbott Medical Optics. Abbott Medical Optics was the ophthalmic-surgery business of Abbott Laboratories and had roots in Advanced Medical Optics, a company Abbott acquired in 2009. Before the acquisition by Johnson & Johnson, the business supplied technologies for cataract surgery, refractive surgery, laser vision correction, and ophthalmic diagnostics and accessories. In September 2016, Johnson & Johnson announced an agreement to acquire Abbott Medical Optics for approximately $4.325 billion in cash. Johnson & Johnson presented the transaction as a way to strengthen its global vision platform and complement its existing contact-lens business with surgical ophthalmology. The acquisition included intraocular lenses, phacoemulsification systems, ophthalmic lasers, and related products. The transaction was subject to customary closing conditions and regulatory review. Johnson & Johnson completed the acquisition in February 2017. The former Abbott Medical Optics activities were incorporated into Johnson & Johnson's Vision organization, which later used names including Johnson & Johnson Vision Surgical and Johnson & Johnson Surgical Vision for the surgical portion of the business. The organization remained a subsidiary business rather than a separately listed company. Following integration, the surgical portfolio continued to be organized around cataract and refractive procedures. Its cataract offerings included the TECNIS family of intraocular lenses and surgical systems associated with phacoemulsification. Its refractive-surgery activities included excimer-laser products and, later, femtosecond-laser technologies. The company also expanded its intraocular-lens portfolio, including the TECNIS Synergy presbyopia-correcting lens, which received United States approval in 2021 and was subsequently launched commercially. Johnson & Johnson has continued to present surgical ophthalmology as part of Johnson & Johnson MedTech's broader vision strategy. The business serves eye surgeons and healthcare institutions, and its performance depends on procedure volumes, product approvals, clinical evidence, training, hospital purchasing, and market access. Public naming is not fully uniform: corporate releases may use Johnson & Johnson Vision, while industry references may distinguish the surgical unit as Johnson & Johnson Surgical Vision. Accordingly, the subject is best understood as a business brand and operating unit within Johnson & Johnson rather than as an autonomous corporation.
- 2021
TECNIS Synergy receives United States approval and launches
[3]Johnson & Johnson Vision announced the United States launch of the TECNIS Synergy intraocular lens after FDA approval.
- 2017
Acquisition completed
[2]Johnson & Johnson completed the acquisition and incorporated the ophthalmic-surgery portfolio into its Vision organization.
- 2016
Johnson & Johnson announces Abbott Medical Optics acquisition
[1]Johnson & Johnson announced an agreement to acquire Abbott Medical Optics for approximately $4.325 billion in cash.
- 2009
Abbott acquires Advanced Medical Optics
[4]Abbott completed its acquisition of Advanced Medical Optics, creating the Abbott Medical Optics platform that later became the foundation of Johnson & Johnson's surgical-vision business.
Products and positioning
A global ophthalmic-surgery technology and device business serving cataract, refractive, and related eye-care procedures through surgical implants, capital equipment, systems, and procedural consumables.
Cataract surgery
TECNIS intraocular lenses
A family of implanted lenses used to replace the eye's natural lens during cataract surgery. The range has included monofocal, toric, extended-depth-of-focus, and multifocal or presbyopia-correcting designs, subject to approval and availability in individual markets.
Cataract-surgery equipment
VERITAS Vision System
A phacoemulsification and cataract-surgery platform designed to support lens removal and related ophthalmic procedures. It represents the capital-equipment side of the surgical-vision portfolio and is marketed to ophthalmic surgeons and operating facilities.
Refractive surgery
ELITA Femtosecond Laser
A femtosecond-laser platform for corneal refractive procedures. The system is associated with Johnson & Johnson Vision's effort to broaden its refractive-surgery technology portfolio beyond implanted lenses and conventional laser-vision-correction equipment.
Presbyopia-correcting intraocular lens · 2021
TECNIS Synergy
A presbyopia-correcting intraocular lens designed for cataract patients. Johnson & Johnson Vision announced its United States launch in 2021 after FDA approval, positioning it within the company's premium cataract-lens portfolio.
Brand decisions
2021
Launch TECNIS Synergy intraocular lensProduct launchBackground
Johnson & Johnson Vision expanded its premium cataract-surgery portfolio with a presbyopia-correcting intraocular lens.
Action taken
The company announced the United States commercial launch of TECNIS Synergy after FDA approval.
Aftermath
The product became part of the TECNIS family and the company's premium intraocular-lens offering.
2016
Acquire Abbott Medical OpticsM&ABackground
Johnson & Johnson sought to expand its vision activities from contact lenses into surgical ophthalmology and related medical devices.
Action taken
The company agreed to purchase Abbott Medical Optics for approximately $4.325 billion in cash, subject to regulatory and other closing conditions.
Aftermath
The transaction closed in 2017, and the acquired portfolio became part of Johnson & Johnson's Vision organization.
Announced transaction value. Approximately $4.325 billion (2016 announcement)
Recent events
- 2021
Johnson & Johnson introduces the TECNIS Synergy intraocular lens[3]
Product launch
Johnson & Johnson Vision announced the United States launch of the TECNIS Synergy intraocular lens for cataract patients following regulatory approval.
- 2017
Johnson & Johnson completes acquisition of Abbott Medical Optics[2]
M&A
Johnson & Johnson completed the acquisition after the transaction received the required regulatory clearances, bringing Abbott Medical Optics into the company's vision businesses.
- 2016
Johnson & Johnson agrees to acquire Abbott Medical Optics[1]
M&A
Johnson & Johnson announced an agreement to acquire Abbott Laboratories' Medical Optics business, adding ophthalmic surgical products and technologies to its vision portfolio.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/johnson-and-johnson-surgical-vision · Editorial policy · How profiles are compiled